ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, Somlyai and colleagues have highlighted the structural similarity between phenformin and imatinib, proposing that this TKI might actually be targeting metabolic functions of CML cells in addition to BCR-ABL signalling [147].